Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 125,000 | 175,000 | 421,000 | 202,510 | 176,306 |
| Marketable Securities | 167,000 | 238,000 | 259,000 | 222,738 | 311,279 |
| Receivables | 200,000 | 121,000 | 158,000 | 112,543 | 124,464 |
| Inventories | 59,000 | 55,000 | 52,000 | 52,200 | 46,498 |
| TOTAL | $606,000 | $657,000 | $951,000 | $643,206 | $719,788 |
| Non-Current Assets | |||||
| PPE Net | 235,000 | 239,000 | 244,000 | 249,961 | 255,763 |
| Investments And Advances | 144,000 | 121,000 | 57,000 | 22,067 | 51,454 |
| Intangibles | 216,000 | 218,000 | 220,000 | 217,349 | 219,139 |
| Other Non-Current Assets | 63,000 | 61,000 | 60,000 | 57,862 | 60,121 |
| TOTAL | $658,000 | $639,000 | $581,000 | $547,239 | $586,477 |
| Total Assets | $1,264,000 | $1,296,000 | $1,532,000 | $1,190,445 | $1,306,265 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 39,000 | 42,000 | 31,000 | 40,573 | 34,242 |
| Accrued Expenses | 221,000 | 194,000 | 265,000 | 220,526 | 180,792 |
| Other current liabilities | 91,000 | 89,000 | 88,000 | 66,781 | 66,444 |
| TOTAL | $351,000 | $325,000 | $384,000 | $340,022 | $293,244 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,174,000 | 1,177,000 | 1,198,000 | 811,206 | 831,677 |
| TOTAL | $1,204,000 | $1,207,000 | $1,228,000 | $841,264 | $861,735 |
| Total Liabilities | $1,555,000 | $1,532,000 | $1,612,000 | $1,181,286 | $1,154,979 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 98,589 | 98,489 | 96,630 | 96,478 | 96,372 |
| Common Shares | N/A | N/A | N/A | 96 | 96 |
| Retained earnings | -4,809,000 | -4,717,000 | -4,532,000 | -4,403,288 | -4,222,875 |
| Other shareholders' equity | 10,000 | 10,000 | 9,000 | 8,820 | 7,732 |
| TOTAL | $-291,000 | $-236,000 | $-80,000 | $9,159 | $151,286 |
| Total Liabilities And Equity | $1,264,000 | $1,296,000 | $1,532,000 | $1,190,445 | $1,306,265 |